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Edited by Gianni CesareniAbstract Buforin II (BF2) is an antimicrobial peptide that is
hypothesized to kill bacteria by entering cells and binding nucleic
acids. To further investigate this proposed mechanism, we used
computer modeling and experimental measurements to consider
the interactions between BF2 and DNA. Computational and
experimental results imply that the peptide forms speciﬁc inter-
actions with DNA. Moreover, we observe a general correlation
between DNA aﬃnity and antimicrobial activity for a series of
BF2 variants. Thus, our results support the proposed mechanism
for BF2 and provide a useful approach for evaluating the nucleic
acid interactions of other antimicrobial peptides.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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dynamics1. Introduction
Although the majority of antimicrobial peptides kill cells
through membrane disruption [1], a few peptides, such as pyr-
rhocoricin [2] and indolicidin [3], act by entering bacterial cells
and interfering with some critical physiological process. Bufo-
rin II (BF2) has also been hypothesized to target intracellular
processes in bacteria. BF2 is a 21-amino acid long peptide ac-
tive against a wide range of bacteria [4]. It shares complete se-
quence identity with a portion of histone H2A that directly
interacts with nucleic acids. In fact, researchers proposed that
BF2 kills bacteria by entering cells and interacting with nucleic
acids [5]. In addition to homology with histone H2A, this pro-
posed mechanism was based on two observations. First, BF2
readily enters bacterial cells in vivo [4,5] and lipid vesicles
in vitro [6] without causing signiﬁcant membrane permeabiliza-
tion. Second, BF2 can bind DNA and RNA in vitro [5].
Although the proposed mechanism is quite intriguing, this
data does not directly connect nucleic acid binding to antimi-
crobial activity. Moreover, it is unclear whether there areAbbreviations: BF2, buforin II; MD, molecular dynamics; FID,
ﬂuorescent intercalator displacement; MM-GBSA, molecular mechan-
ics-Generalized Born surface area
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doi:10.1016/j.febslet.2008.04.036speciﬁc interactions between BF2 and nucleic acids or whether
they only bind because of their opposite net charges. Although
previous studies have considered the structure of BF2 in
solution and bound to membranes [6–8], none have character-
ized how BF2 binds nucleic acids on the molecular-level. In
this paper, we used computational and experimental tech-
niques to characterize the nucleic acid binding of BF2 and
investigate how this binding relates to antimicrobial activity.2. Materials and methods
2.1. Molecular modeling
Since the BF2 sequence is identical to a portion of histone H2A, we
developed an initial model of BF2 bound to DNA based on a Xenopus
laevis histone Æ DNA complex crystal structure (1AOI) [9]. Speciﬁcally,
we extracted residues 16–36 from chain G of this structure along with
the adjacent section of DNA (bases 107–127 of chain I and bases 166–
186 of chain J). The residue of the extracted peptide corresponding to
Phe 10 of BF2 was mutated to Trp for consistency with experimental
measurements described below. This F10W mutation does not signiﬁ-
cantly aﬀect the antimicrobial activity or membrane interactions of
BF2 [6]. The complex was reﬁned using molecular dynamics (MD) sim-
ulations in AMBER 8.0 [10] with the ﬀ03 force ﬁeld. For simulations,
the complex was solvated with 8282 TIP3P waters, and Na+ ions were
added to neutralize the overall system charge. All Arg and Lys residues
and the N- and C-termini were ionized, while the single His sidechain
was left uncharged. Before MD, the system was subjected to 100 steps
of steepest descents minimization. The minimized system was heated to
300 K over 20 ps, and the trajectory was extended to a total length of
10 ns with constant temperature (300 K) and isotropic constant pres-
sure (1 bar). A timestep of 2 fs was used, and bonds to hydrogen were
constrained using SHAKE [11]. Short-range interactions were calcu-
lated with a cutoﬀ of 8 A˚, and long-range electrostatics were calculated
using PME [12]. A control simulation (data not shown) with a shorter
DNA strand (13 bp) yielded similar properties.
MD analyses were performed using tools in the AMBER suite.
Interaction energies were calculated with the molecular mechanics-
Generalized Born surface area (MM-GBSA) approach [13], averaging
snapshots saved every 10 ps from the last 5 ns of the MD simulation.
Calculated interaction energies showed the same trends when averaged
over the last 2 ns of the simulation. The solvation component of inter-
action energy was calculated using a GB/SA approach [14], with a salt
concentration of 100 mM and a dielectric constant of 1 and 80 for the
solute and solvent, respectively.
2.2. Fluorescent intercalator displacement assay
Chemically synthesized wild type and mutant BF2 at >95% purity
was obtained from EZ-Biolab (Westﬁeld, IN). All peptides had un-
blocked termini and included the F10W mutation described above.
DNA oligos with the same sequence as the portion of DNA directly
bound by BF2 in the MD simulation (AAATACACTTTTGGT and
its complement) were obtained from IDT (Coralville, IA).
DNA binding was measured using a ﬂuorescence intercalator
displacement (FID) assay [15,16]. Brieﬂy, a quartz cuvette was loaded
with thiazole orange (0.55 lM) in STE buﬀer (10 mM Tris, 50 mMblished by Elsevier B.V. All rights reserved.
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measured (excitation 509 nm, emission 527 nm) and normalized to
0% relative ﬂuorescence. DNA in STE buﬀer was added to the cuvette
(1.1 lM bp ﬁnal concentration). After equilibrating for 5 min the ﬂuo-
rescence of this solution was measured and normalized to 100% rela-
tive ﬂuorescence. Aliquots of a peptide solution were then added
with mixing, allowing 5 min of incubation after each addition before
measuring ﬂuorescence. C50 (concentration of peptide required to re-
duce ﬂuorescence to 50% of the initial emission) was determined by
a curve ﬁt to data; all ﬁts for data included had R2 > 0.95. Relative
DNA binding constants were obtained by comparing the inverse of
C50 [15].
2.3. Radial diﬀusion assay
The antibacterial activity of BF2 variants was measured using the
radial diﬀusion assay of Lehrer and co-workers [17]. For the assay, a
culture of Escherichia coli in LB media grown overnight (14–16 h) at
37 C was diluted 1:1000 into 50 ml of TSB and incubated with shaking
for 2.5 h at 37 C. This culture was then centrifuged at 900 · g for
10 min at 4 C. The resulting pellet was washed with 10 ml of sodium
phosphate buﬀer (10 mM, pH 7.4), pelleted again, and resuspended in
5 ml of buﬀer. 4 · 106 CFU were mixed with 10 ml of molten underlayFig. 2. (A) MM-GBSA interaction energy of BF2 sidechains with DNA; e
weaker (hatched) and stronger (gray) DNA interactions selected for experim
ﬁnal simulation frame with only the backbone shown for DNA and Arg 2/A
Fig. 1. (A) Superimposed BF2 structures from the BF2 Æ DNA
complex before (white) and after (gray) the MD simulation. (B) The
BF2 (gray cartoon) Æ DNA (white spaceﬁlling) complex at the end of
the MD simulation.agar (1:100 TSB, 1% agarose (w/v), 10 mM sodium phosphate, pH 7.4)
at 42 C with vortexing for 15 s. This agar was poured into a Petri dish
and allowed to gel. Wells were formed in the solid media using a pip-
ette attached to a bleach trap, and 2.5 ll of sterile peptide solutions
(4 · 104 M) were added to wells. After incubating for 3 h at 37 C,
the plates were covered with an additional layer of overlay agar (6%
(w/v) TSB, 1% (w/v) agarose) and incubated overnight at 37 C. After
overnight incubation, the diameter of the zone without bacterial
growth around each well was measured. Measurements from 48 diﬀer-
ent wells on plates from at least two separate experiments were aver-
aged for each peptide.3. Results and discussion
3.1. Molecular modeling of BF2 Æ DNA interactions
To create an initial model of BF2 bound to nucleic acids, we
extracted the histone residues identical to BF2 and the region
of DNA bound by these residues from a crystal structure of the
X. laevis histone Æ DNA complex [9]. However, the pro-
tein Æ DNA interactions in the large histone complex could dif-
fer from those that would occur for the short BF2 peptide.
Therefore, we reﬁned the extracted peptide Æ DNA complex
using a 10 ns MD simulation. In this simulation, the peptide
structure rapidly equilibrated to an overall structure similar
to the initial model (Fig. 1A), with BF2 bound in the major
groove of DNA (Fig. 1B). The ﬁnal peptide structure had a
Ca RMS deviation of 1.6 A˚ from the initial histone conforma-
tion. However, some adjustments did occur in speciﬁc residue
positions, such as the Arg 5 sidechain discussed below.
The MM-GBSA method of Kollman et al. [13] was used to
calculate the interaction energy between each individual BF2
sidechain and DNA. As expected, the strongest predicted
interactions between BF2 and DNA involved basic sidechains
(Fig. 2A). All H-bonding interactions between basic BF2 side-
chains and DNA involved phosphate groups in the nucleic acid
backbone. Since these groups would be identical for all nucleic
acid bases, BF2 likely targets nucleic acids in a non-sequence
speciﬁc manner.
Interestingly, the interaction energies are signiﬁcantly weak-
er for some speciﬁc basic sidechains (e.g. Arg 5 and Lys 21)
compared to others (e.g. Arg 2 and Arg 20) (Fig. 2A and B).
This observation implies that BF2 does not only bind DNArrors are expressed as standard deviations. Energies of residues with
ental mutagenesis are highlighted. (B) BF2 Æ DNA complex from the
rg 20 (gray) and Arg 5/Lys 21 (white) in spaceﬁlling.
Fig. 4. Correlation between relative DNA binding constants and
antimicrobial activity for BF2 variants. The R20A and R2A/R5A
variants are shown as an open circle and a solid diamond, respectively.
Errors are expressed as standard errors; errors for antimicrobial
activity are smaller than the symbols.
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ionic peptide and nucleic acids. The weaker nucleic acid inter-
action of Lys 21 is not surprising since the adjacent negative
charge of the peptide C-terminus repels that entire residue
from the nucleic acid backbone. However, the weaker interac-
tion of Arg 5 arises because this sidechain, which is in direct
DNA backbone contact in the histone structure, moves away
from DNA in the MD simulation. A control simulation with
a shorter DNA strand showed similar structural properties
for BF2 and a similar trend in interaction energies for many
basic residues (e.g. Arg 2, Arg 20, Arg 5, and Lys 21), although
the relative interaction energies of Arg 14 and Arg 17 were
more equivalent in this simulation.
3.2. Experimental measurements of BF2 Æ DNA interactions
To verify that speciﬁc interactions occur between BF2 side-
chains and DNA, we experimentally compared the DNA bind-
ing aﬃnity of BF2 mutants. Four mutants were chosen based
on the MM-GBSA analysis (Fig. 2), two to residues with
stronger predicted interaction energies (R2A and R20A) and
two to residues with weaker predicted interaction energies
(R5A and K21A). These residues were chosen for mutations
since they showed consistent interaction energy trends in both
our MD simulations.
The relative DNA binding constants for these mutants were
measured using a FID assay [15,16], which has been used to
measure the binding of other compounds to the major and
minor grooves of DNA [16,18]. The relative binding constants
from these measurements follow a trend consistent with the
predicted interaction energies of the peptides, as R2A and
R20A mutations aﬀect DNA binding more than R5A and
K21A mutations (Fig. 3). However, the R5A and K21A muta-
tions clearly decrease the DNA aﬃnity of the peptide. One
likely reason for the decreased aﬃnity of R5A and K21A is
that neutralizing any positively charged sidechain would de-
crease the non-speciﬁc electrostatic attraction between BF2
and DNA. However, it is also possible that BF2 can bind
DNA in other conformations that have more direct interac-
tions of these sidechains with DNA, although these conforma-
tions were not sampled in our simulations. Nonetheless, the
clear diﬀerences in binding for diﬀerent charge neutralizationFig. 3. Average relative DNA binding constants with standard errors
of BF2 variants measured using the FID assay. Data for mutations to
residues with weaker (hatched) and stronger (gray) predicted DNA
interactions are highlighted.mutants conﬁrm that speciﬁc BF2 sidechains do have stronger
interactions with DNA.
3.3. Correlation of DNA aﬃnity and antimicrobial activity
We also used our series of BF2 variants to determine
whether DNA binding aﬃnity is related to the peptides anti-
microbial activity. To this end, we measured the antibacterial
activity of the peptides using a radial diﬀusion assay [17,19],
which has been used in previous studies of BF2 and other his-
tone-derived antimicrobial peptides [20–22]. In this assay, a
peptide with greater antimicrobial activity causes a larger re-
gion of restricted bacterial growth on the plates. These studies
also included one double-mutant, R2A/R5A, for which we also
measured the DNA binding aﬃnity using the FID assay.
In general, antimicrobial activity correlated with the relative
DNA binding aﬃnity of the peptides (Fig. 4). This relationship
supports the assertion that BF2 kills bacteria through its inter-
actions with nucleic acids, since peptides with reduced DNA
interactions showed decreased antibacterial activity. One vari-
ant, R20A, deviated from the overall correlation between anti-
bacterial activity and DNA binding (Fig. 4), and it would be
interesting for future studies to consider why this deviation
arises. For example, the R20A modiﬁcation might aﬀect mem-
brane interactions, altering the peptides membrane transloca-
tion or permeabilization properties.4. Summary
The computational and experimental results described in
this paper provide the ﬁrst molecular-level insights into
BF2 Æ DNA interactions. Interestingly, these results imply that
BF2 forms speciﬁc interactions with DNA. Moreover, disrupt-
ing BF2 Æ DNA interactions generally decreased the antibacte-
rial activity of the peptide. This observation supports the
proposed antimicrobial mechanism for BF2 [5], although our
data does not preclude BF2 having another yet unidentiﬁed
intracellular target.
Recent studies have identiﬁed other histone-derived antimi-
crobial peptides [20–25]. As well, other peptides are proposed
to target bacteria through interactions with nucleic acids
[26,27]. An approach similar to the one used to consider BF2
in this study could be quite useful for future investigations
1718 E.T. Uyterhoeven et al. / FEBS Letters 582 (2008) 1715–1718probing the nucleic acid interactions and mechanism of these
other peptides.
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